Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study.

Abstract:

UNLABELLED:In this randomised, placebo-controlled 12-week study, sixty healthy postmenopausal women received either placebo (N = 16) or daily 2 mg micronised oestradiol, either unopposed (N = 16, E2 group) or combined with a progestagen for 14 days of each cycle (N = 28, E2+P group). RESULTS:As compared to placebo, plasma levels of AT III were reduced only in the E2 group (approximately 28%), plasma levels of protein C decreased only in the E2+P group (approximately 4%) and plasma levels of protein S decreased in both the E2 and E2+P group (approximately 21%). In both the E2 and E2+P groups, the plasma levels of factor VII (antigen and activity) showed a borderline significant increase (approximately 10%), whereas no significant change was observed in active factor VII. Plasma levels of tissue-type plasminogen activator (approximately 22%), urokinase plasminogen activator (approximately 25%) and plasminogen activator inhibitor type-1 (approximately 43%) decreased in the E2 and E2+P groups, whereas those of plasminogen increased (approximately 12%). Treatment was associated with an increase in levels of prothrombin fragment 1+2 (approximately 31%), but levels of thrombin-antithrombin III complexes, and of plasmin-alpha2-antiplasmin complexes and total fibrin(ogen) degradation products did not change significantly. CONCLUSION:Short-term E2 and E2+P treatment is associated with a shift in the procoagulant-anticoagulant balance towards a procoagulant state. A substantial proportion of women do not have a net increase in fibrinolytic activity. These data may be relevant in explaining the increased risk of venous thromboembolism associated with ERT and HRT, and possibly also in explaining the negative results of the Heart and Estrogen/progestin Replacement Study.

journal_name

Thromb Haemost

authors

van Baal WM,Emeis JJ,van der Mooren MJ,Kessel H,Kenemans P,Stehouwer CD

keywords:

subject

Has Abstract

pub_date

2000-01-01 00:00:00

pages

29-34

issue

1

eissn

0340-6245

issn

2567-689X

pii

00010029

journal_volume

83

pub_type

临床试验,杂志文章,随机对照试验
  • Heparin reverses the procoagulant properties of stimulated endothelial cells.

    abstract::We examined the ability of unfractionated heparin to modulate the procoagulant activities of stimulated endothelial cells (EC). Confluent human venous umbilical EC were incubated with heparin before or after stimulation, then rinsed extensively to eliminate any heparin in the solution. EC, stimulated for 4 h with endo...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Cadroy Y,Gaspin D,Dupouy D,Lormeau JC,Boneu B,Sié P

    更新日期:1996-01-01 00:00:00

  • Pretreatment with oral anticoagulants decreases platelet activation in patients before and after percutaneous coronary intervention.

    abstract:BACKGROUND:Platelet activation plays a major role in acute vessel closure after coronary angioplasty. In the randomized Balloon Angioplasty and Anticoagulation Study (BAAS), pretreatment with oral anticoagulants in addition to aspirin resulted in a 47% reduction of acute complications as compared with aspirin alone. Th...

    journal_title:Thrombosis and haemostasis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: ten Berg JM,Gerritsen WB,Haas FJ,Kelder JC,Verheugt FW,Thijs Plokker HW

    更新日期:2002-12-01 00:00:00

  • Dysfunctional plasminogen in full term newborn--study of active site of plasmin.

    abstract::The functional activity and active site of plasmin in full-term newborns have been studied and compared to those in adults in order to investigate the nature of the abnormality found in newborn plasminogen described in a previous paper. The functional activity of newborn plasminogen measured on chromogenic substrate w...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Benavent A,Estellés A,Aznar J,Martinez-Sales V,Gilabert J,Fornas E

    更新日期:1984-02-28 00:00:00

  • Temporal variability in the antiplatelet effects of clopidogrel and aspirin after elective drug-eluting stent implantation. An ADAPT-DES substudy.

    abstract::Given conflicting data on temporal variability in pharmacodynamic platelet responses to clopidogrel, we investigated platelet reactivity on clopidogrel and aspirin for up to six months after elective percutaneous coronary intervention (PCI) with drug-eluting stents. Platelet reactivity was determined in 102 patients b...

    journal_title:Thrombosis and haemostasis

    pub_type: 临床试验,杂志文章

    doi:10.1160/TH15-03-0257

    authors: Nührenberg TG,Stratz C,Leggewie S,Hochholzer W,Valina CM,Gick M,Kirtane AJ,Stone GW,Neumann FJ,Trenk D

    更新日期:2015-11-01 00:00:00

  • Comparative study of inhibitory antibody derivatives towards thrombin activatable fibrinolysis inhibitor.

    abstract::Thrombin activatable fibrinolysis inhibitor (TAFI) attenuates fibrinolysis and is considered as an attractive drug target. We generated two different antibody fragments, an antigen-binding fragment (Fab) and a single-chain variable fragment (scFv), derived from three distinct monoclonal antibodies (MAs) that inhibit t...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH08-09-0834

    authors: Develter J,Dewilde M,Gils A,Declerck PJ

    更新日期:2009-07-01 00:00:00

  • C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study.

    abstract::Previous studies have shown an association between serum C-reactive protein (CRP) and cardiovascular disease (CVD) risk. The roles of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFalpha) are less well established. The aim of the present study was to analyze the associations of CRP, IL-6 and TNFalpha with in...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH05-08-0571

    authors: Tuomisto K,Jousilahti P,Sundvall J,Pajunen P,Salomaa V

    更新日期:2006-03-01 00:00:00

  • Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence.

    abstract::Despite great efforts in stroke research, disability and recurrence rates in ischaemic stroke remain unacceptably high. To address this issue, one potential target for novel therapeutics is the glycoprotein von Willebrand factor (vWF), which increases in thrombogenicity especially under high shear rates as it bridges ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0038-1648251

    authors: Buchtele N,Schwameis M,Gilbert JC,Schörgenhofer C,Jilma B

    更新日期:2018-06-01 00:00:00

  • Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.

    abstract::The efficacy and safety of dabigatran for treatment of venous thromboembolism (VTE) were demonstrated in two trials. It is unclear if the results pertain to patients with cancer and VTE. Data from two randomised trials comparing dabigatran and warfarin for acute VTE were pooled. Primary efficacy outcome was symptomati...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH14-11-0977

    authors: Schulman S,Goldhaber SZ,Kearon C,Kakkar AK,Schellong S,Eriksson H,Hantel S,Feuring M,Kreuzer J

    更新日期:2015-07-01 00:00:00

  • The measurement of human plasma antiplasmin activity by radial diffusion assay.

    abstract::An assay of human antiplasmins has been developed utilizing radial diffusion of plasma from wells cut in plasmin-enriched, fibrinogen-agarose plates. After diffusion the fibrinogen is clotted. Zones of fibrin protected from background fibrinolysis develop as the result of plasma antiplasmin activity. A pooled plasma s...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Andes WA

    更新日期:1978-04-30 00:00:00

  • Occurrence of Soluble Very High Molecular Weight Fibrinogen Complexes in Hypercoagulable States. An in vitro and in vivo Study on their Features.

    abstract::The gel-chromatography of the beta-alanine precipitate of human plasma and of purified fibrinogen shows the presence of different classes of fibrinogen complexes. A first class of complexes is detectable in correspondence with the ascending branch of the fibrinogen peak ("shoulder" complexes or high molecular weight f...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0038-1657059

    authors: Serneri GGE,Gensini GF,Abbate R,Favilla S

    更新日期:1979-07-01 00:00:00

  • Plasma levels of bradykinin are suppressed in factor XII-deficient mice.

    abstract::A genetically-transmissible factor (F) XII-inactivated allele has been produced in mice by targeted replacement of exons 3-8 of the FXII gene with the neomycin resistance gene. Interbreeding of these mice provided offspring homozygous for two inactivated FXII alleles (FXII(-/-)). Male and female FXII-deficient mice br...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH06-03-0128

    authors: Iwaki T,Castellino FJ

    更新日期:2006-06-01 00:00:00

  • Tyrosine phosphorylation / dephosphorylation balance is involved in thrombin-evoked microtubular reorganisation in human platelets.

    abstract::We have investigated the intracellular mechanisms involved in microtubular remodelling by thrombin and its possible involvement in platelet aggregation and secretion. Platelet stimulation with thrombin induces a time- and concentration-dependent regulation of the microtubular content, which was found to be maximally e...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Bouaziz A,Amor NB,Woodard GE,Zibidi H,López JJ,Bartegi A,Salido GM,Rosado JA

    更新日期:2007-08-01 00:00:00

  • Human thrombi contain an abundance of active thrombin.

    abstract::This study assessed the abundance and activity of thrombin in human thrombi. removed at autopsy or during surgery. Arterial and venous thrombus sections showed thrombin activity by in situ zymography, based on conversion of fibrinogen to fibrin. Hirudin or antibodies to thrombin abolished the activity. Thrombin activi...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Mutch NJ,Robbie LA,Booth NA

    更新日期:2001-10-01 00:00:00

  • Quantification of Platelet Contractile Movements during Thrombus Formation.

    abstract::Imaging methods based on time-lapse microscopy are important tools for studying the dynamic events that shape thrombus formation upon vascular injury. However, there is a lack of methods to translate the vast amount of visual data generated in such experiments into quantitative variables describing platelet movements ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0038-1668151

    authors: Tunströmer K,Faxälv L,Boknäs N,Lindahl TL

    更新日期:2018-09-01 00:00:00

  • Plasminogen activation by invasive human pathogens.

    abstract::In this review the interaction between invasive human pathogens expressing plasmin(ogen) receptors and/or producing plasminogen activators with the human plasmin(ogen) system is described. Evidence is presented for multiple mechanisms by which human pathogens can acquire a surface bound form of plasmin that cannot be ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章,评审

    doi:

    authors: Boyle MD,Lottenberg R

    更新日期:1997-01-01 00:00:00

  • Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis.

    abstract::Platelet adhesion and aggregation at the sites of vascular injury are key events for thrombosis and haemostasis. It has been well demonstrated that interaction between glycoprotein (GP) Ibα and von Willebrand factor (VWF) initiates platelet adhesion and contributes to platelet aggregation, particularly at high shear. ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH13-06-0490

    authors: Lei X,Reheman A,Hou Y,Zhou H,Wang Y,Marshall AH,Liang C,Dai X,Li BX,Vanhoorelbeke K,Ni H

    更新日期:2014-02-01 00:00:00

  • Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists.

    abstract::Factor Xa (fXa)-inhibitors are as effective and safer than vitamin-K-antagonists (VKA) in the treatment of venous thromboembolism (VTE). We previously classified the severity of clinical presentation and course of all major bleeding events from the EINSTEIN, AMPLIFY and HOKUSAI-VTE trials separately. The current aim w...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH16-12-0946

    authors: Bleker SM,Brekelmans MPA,Eerenberg ES,Cohen AT,Middeldorp S,Raskob G,Büller HR

    更新日期:2017-10-01 00:00:00

  • All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism.

    abstract::Oral anticoagulants used for the primary treatment of venous thromboembolism (VTE) include warfarin and the more recently introduced direct oral anticoagulants (DOACs), including rivaroxaban, apixaban, dabigatran and edoxaban. Information on the comparative safety of these medications in routine clinical practice is l...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0038-1668521

    authors: Roetker NS,Lutsey PL,Zakai NA,Alonso A,Adam TJ,MacLehose RF

    更新日期:2018-09-01 00:00:00

  • Importance of protease inhibition in studies on purified factor VIII (antihaemophilic factor).

    abstract::According to some authors factor VIII procoagulant activity may be dissociable from carrier protein (MW approximately 2 X 10(6) by agarose gel filtration, e.g. at high ionic strength. We were able to reproduce this phenomenon. However, addition of protease inhibitor (Trasylol) prevented the appearance of low molecular...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Beck EA,Bachmann P,Barbier P,Furlan M

    更新日期:1976-02-29 00:00:00

  • The subendothelium of the HMEC-1 cell line supports thrombus formation in the absence of von Willebrand factor and collagen types I, III and VI.

    abstract::The macromolecular composition of the extracellular matrix (ECM) produced by the human microvascular endothelial cell line (HMEC-1) was determined by ELISA and its thrombogenicity was studied in blood perfusion assays. Results were compared with those obtained with the ECM produced by human umbilical vein endothelial ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Bonnefoy A,Harsfalvi J,Pfliegler G,Fauvel-Lafève F,Legrand C

    更新日期:2001-03-01 00:00:00

  • Animal models of vulnerable plaque. Clinical context and current status.

    abstract::There is increasing recognition of the importance of vulnerable plaque and acute plaque rupture leading to thrombosis, in the pathogenesis of acute coronary syndromes. This is fueling a number of developments, including novel imaging modalities and potential plaque stabilization therapies. However, to date, no animal ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章,评审

    doi:10.1160/TH03-06-0374

    authors: Lowe HC,Jang IK,Khachigian LM

    更新日期:2003-11-01 00:00:00

  • Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I.

    abstract::Lupus anticoagulants (LA) are immunoglobulins directed to either prothrombin or Beta-2-glycoprotein 1(beta1GPI) bound to phospholipids. Most patients with LA have both beta2GPI- and prothrombin-dependent antibodies. Several recent reports have shown that LA is more strongly associated with thrombosis than anticardioli...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章,多中心研究

    doi:

    authors: Arnout J,Meijer P,Vermylen J

    更新日期:1999-06-01 00:00:00

  • Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines.

    abstract::Induction of procoagulant factors in malignant cells is considered to be the major cause of coagulation disorders in cancer. Thrombomodulin (TM), a negative regulator of coagulation was also found to be expressed in cancer cells. We report here evidence for another anticoagulant, the endothelial cell protein C recepto...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Tsuneyoshi N,Fukudome K,Horiguchi S,Ye X,Matsuzaki M,Toi M,Suzuki K,Kimoto M

    更新日期:2001-02-01 00:00:00

  • The role of monocytes in thrombotic disorders. Insights from tissue factor, monocyte-platelet aggregates and novel mechanisms.

    abstract::Although, the main physiological role of monocytes is attributed to innate immunity (that is, phagocytosis) and the development of tissue macrophages and dendritic cells, the pathophysiological role of these goes far behind these (simplistic) limits. Indeed, monocytes constitute a major source of blood tissue factor, ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章,评审

    doi:10.1160/TH09-01-0023

    authors: Shantsila E,Lip GY

    更新日期:2009-11-01 00:00:00

  • Characterization of beta2-glycoprotein I binding to phospholipid membranes.

    abstract::The plasma protein beta2-glycoprotein I (beta2-GPI) is a major target of autoantibodies in patients with the antiphospholipid syndrome. To understand the physiological function of beta2-GPI and its potential role in the pathophysiology of the antiphospholipid syndrome, the binding of beta2-GPI to phospholipid membrane...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Harper MF,Hayes PM,Lentz BR,Roubey RA

    更新日期:1998-10-01 00:00:00

  • Hereditary and acquired thrombophilia in patients with upper extremity deep-vein thrombosis. Results from the MAISTHRO registry.

    abstract::The prevalence of coagulation disorders in patients with upper extremity deep-vein thrombosis (UE-DVT) is unknown due to only a few observational studies of limited size reporting varying results. Therefore, we aimed to evaluate the prevalence of thrombophilia in patients with UE-DVT compared to patients with lower ex...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Linnemann B,Meister F,Schwonberg J,Schindewolf M,Zgouras D,Lindhoff-Last E,MAISTHRO registry.

    更新日期:2008-09-01 00:00:00

  • Low Affinity Platelet Factor 4 and High Affinity Platelet Factor 4 - Two Antiheparin Factors Secreted by Human Platelets.

    abstract:: ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0038-1657075

    authors: Niewiarowski S,Rucinski B,Budzynski AZ

    更新日期:1979-07-01 00:00:00

  • The burden of inhibitors in haemophilia patients.

    abstract::The burden of disease in haemophilia patients has wide ranging implications for the family and to society. There is evidence that having a current inhibitor increases the risk of morbidity and mortality. Morbidity is increased by the inability to treat adequately and its consequent disabilities, which then equates to ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH16-01-0049

    authors: Walsh CE,Jiménez-Yuste V,Auerswald G,Grancha S

    更新日期:2016-08-31 00:00:00

  • Factor VIIa in patients with C1-inhibitor deficiency.

    abstract::In hereditary angioedema (HAE), normal C1-inhibitor (C1-INH) is low and the contact system activated. Recently, the findings of a tissue factor mutant selectively deficient in promoting the conversion of FVII to FVIIa, but with retained cofactor for FVIIa, made it possible to examine reliably the pre-existing content ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Nielsen EW,Morrissey J,Olsen JO,Osterud B

    更新日期:1995-10-01 00:00:00

  • Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin.

    abstract::The prophylactic treatment of haemophilia B and the management of haemophilia A or B with inhibitors demand frequent administrations of coagulation factors due to the suboptimal half-lives of the products commercially available and currently in use, e.g. recombinant factor IX (rFIX) and recombinant factor VIIa (rFVIIa...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章,评审

    doi:10.1160/TH13-03-0213

    authors: Metzner HJ,Pipe SW,Weimer T,Schulte S

    更新日期:2013-11-01 00:00:00